Chris Rallis - Jul 7, 2025 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris Rallis
Stock symbol
FENC
Transactions as of
Jul 7, 2025
Transactions value $
-$9,746
Form type
4
Date filed
7/7/2025, 05:31 PM
Previous filing
Jun 4, 2025
Next filing
Oct 14, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RALLIS CHRIS A Director C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK /s/ Chris Rallis 2025-07-07 0001185945

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $5K +2.13K +3.95% $2.35 55.9K Jul 7, 2025 Direct F1
transaction FENC Common Shares Sale -$9.75K -1.12K -2% $8.71 54.8K Jul 7, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise -$5K -2.13K -1.18% $2.35 178K Jul 7, 2025 Options 2.13K $2.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
F2 Shares sold to satisfy tax obligation on option exercise.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.